Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: brainlung cancerdeterminepatientscell lung
  Phrases that lowered it: trialthe aimdexamethasonecarcinomaaim of
• Primary purpose: other (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 29.4% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 96.0% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC) NCT00744900 · started 2008 · scored riskier than 88% of active trials completed
• WBRT & Erlotinib in Advanced NSCLC and Brain Metastases NCT00554775 · started 2008 · scored riskier than 94% of active trials terminated
• Atezolizumab Plus Bevacizumab in First Line NSCLC Patients NCT03836066 · started 2019 · scored riskier than 86% of active trials completed
• Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis NCT01332929 · started 2010 · scored riskier than 45% of active trials completed
• Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma NCT00761280 · started 2008 · scored riskier than 72% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.